Brandes Investment Partners’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.54M | Buy |
4,281
+237
| +6% | +$118K | 0.02% | 161 |
|
|
2025
Q4 | $1.97M | Buy |
4,044
+1,027
| +34% | +$478K | 0.02% | 169 |
|
|
2025
Q3 | $1.26M | Buy |
3,017
+608
| +25% | +$204K | 0.01% | 166 |
|
|
2025
Q2 | $692K | Buy |
2,409
+585
| +32% | +$175K | 0.01% | 176 |
|
|
2025
Q1 | $562K | Buy |
1,824
+340
| +23% | +$117K | 0.01% | 179 |
|
|
2024
Q4 | $524K | Sell |
1,484
-10,210
| -87% | -$3.75M | 0.01% | 184 |
|
|
2024
Q3 | $4.19M | Sell |
11,694
-8,222
| -41% | -$2.78M | 0.05% | 128 |
|
|
2024
Q2 | $6.33M | Buy |
19,916
+926
| +5% | +$245K | 0.08% | 114 |
|
|
2024
Q1 | $4.36M | Buy |
18,990
+2,897
| +18% | +$654K | 0.06% | 117 |
|
|
2023
Q4 | $3.54M | Buy |
16,093
+884
| +6% | +$204K | 0.05% | 119 |
|
|
2023
Q3 | $3.44M | Buy |
15,209
+689
| +5% | +$159K | 0.07% | 115 |
|
|
2023
Q2 | $3.21M | Sell |
14,520
-110
| -0.8% | -$24.4K | 0.06% | 115 |
|
|
2023
Q1 | $3.28M | Buy |
14,630
+4,670
| +47% | +$1.15M | 0.07% | 115 |
|
|
2022
Q4 | $2.77M | Sell |
9,960
-9,546
| -49% | -$2.41M | 0.08% | 84 |
|
|
2022
Q3 | $4.08M | Sell |
19,506
-1,599
| -8% | -$357K | 0.11% | 110 |
|
|
2022
Q2 | $4.97M | Buy |
21,105
+1,096
| +5% | +$223K | 0.12% | 110 |
|
|
2022
Q1 | $3.59M | Buy |
20,009
+1,432
| +8% | +$273K | 0.08% | 113 |
|
|
2021
Q4 | $4.01M | Sell |
18,577
-276
| -1% | -$54.2K | 0.09% | 113 |
|
|
2021
Q3 | $3.48M | Buy |
18,853
+476
| +3% | +$93.8K | 0.08% | 110 |
|
|
2021
Q2 | $3.3M | Sell |
18,377
-12
| -0.1% | -$2.29K | 0.07% | 110 |
|
|
2021
Q1 | $3.04M | Sell |
18,389
-14,148
| -43% | -$2.36M | 0.07% | 108 |
|
|
2020
Q4 | $4.84M | Sell |
32,537
-27,255
| -46% | -$3.58M | 0.12% | 92 |
|
|
2020
Q3 | $6.04M | Sell |
59,792
-16,571
| -22% | -$1.82M | 0.21% | 82 |
|
|
2020
Q2 | $9.24M | Sell |
76,363
-216,033
| -74% | -$24.3M | 0.28% | 77 |
|
|
2020
Q1 | $27.7M | Buy |
292,396
+1,414
| +0.5% | +$134K | 0.97% | 38 |
|
|
2019
Q4 | $25.6M | Sell |
290,982
-6,131
| -2% | -$539K | 0.61% | 54 |
|
|
2019
Q3 | $23.7M | Buy |
297,113
+74,963
| +34% | +$6.04M | 0.61% | 56 |
|
|
2019
Q2 | $17.3M | Buy |
222,150
+176,048
| +382% | +$16.5M | 0.39% | 66 |
|
|
2019
Q1 | $5.41M | Buy |
46,102
+2,227
| +5% | +$259K | 0.13% | 85 |
|
|
2018
Q4 | $4.78M | Buy |
43,875
+15,111
| +53% | +$1.75M | 0.12% | 89 |
|
|
2018
Q3 | $3.68M | Sell |
28,764
-1,011
| -3% | -$125K | 0.08% | 95 |
|
|
2018
Q2 | $3.37M | Buy |
29,775
+2,845
| +11% | +$313K | 0.08% | 96 |
|
|
2018
Q1 | $3.03M | Buy |
26,930
+13,217
| +96% | +$1.68M | 0.06% | 97 |
|
|
2017
Q4 | $2.03M | Buy |
+13,713
| New | +$1.74M | 0.04% | 119 |
|
Other funds holding UTHR
ACA
VPM
VCM
Brandes Investment Partners's UTHR Position: Q1 2026 in Review
Brandes Investment Partners increased its United Therapeutics (UTHR) stake by 5.9% in Q1 2026, buying an estimated $118K and bringing the position to 4,281 shares worth $2.54M. The position accounts for 0.02% of the portfolio, ranked #161.
Brandes Investment Partners first reported a position in UTHR in Q4 2017 and has held it in 34 quarters since. The position peaked at $27.7M in Q1 2020. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- Brandes Investment Partners held 4,281 shares of United Therapeutics worth $2.54M as of Q1 2026.
- Brandes Investment Partners bought 237 United Therapeutics shares in Q1 2026, an estimated $118K.
- United Therapeutics made up 0.02% of Brandes Investment Partners's portfolio in Q1 2026, its #161 holding.
- Brandes Investment Partners first reported a position in United Therapeutics in Q4 2017 and has held it in 34 quarters since.
- Brandes Investment Partners's United Therapeutics position peaked at $27.7M in Q1 2020.
- 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on Brandes Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.